Abstract
In the past, liver cirrhosis was considered an irreversible phenomenon. However, many experimental data have provided evidence of the reversibility of liver fibrosis. Moreover, multiple clinical studies have also shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples. As various etiologies are associated with liver fibrosis via integrated signaling pathways, a comprehensive understanding of the pathobiology of hepatic fibrogenesis is critical for improving clinical outcomes. Hepatic stellate cells play a central role in hepatic fibrogenesis upon their activation from a quiescent state. Collagen and other extracellular material components from activated hepatic stellate cells are deposited on, and damage, the liver parenchyma and vascular structures. Hence, inactivation of hepatic stellate cells can lead to enhancement of fibrolytic activity and could be a potential target of antifibrotic therapy. In this regard, continued efforts have been made to develop better treatments for underlying liver diseases and antifibrotic agents in multiple clinical and therapeutic trials; the best results may be expected with the integration of such evidence. In this article, we present the underlying mechanisms of fibrosis, current experimental and clinical evidence of the reversibility of liver fibrosis/cirrhosis, and new agents with therapeutic potential for liver fibrosis.
| Original language | English |
|---|---|
| Pages (from-to) | 213-228 |
| Number of pages | 16 |
| Journal | Korean Journal of Internal Medicine |
| Volume | 32 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2017 Jan 1 |
Fingerprint
Keywords
- Fibrosis
- Hepatic stellate cells
- Liver cirrhosis
- Reversal
- Therapy
ASJC Scopus subject areas
- Internal Medicine
Cite this
Reversal of liver cirrhosis : Current evidence and expectations. / Jung, Young Kul; Yim, Hyung Joon.
In: Korean Journal of Internal Medicine, Vol. 32, No. 2, 01.01.2017, p. 213-228.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Reversal of liver cirrhosis
T2 - Current evidence and expectations
AU - Jung, Young Kul
AU - Yim, Hyung Joon
PY - 2017/1/1
Y1 - 2017/1/1
N2 - In the past, liver cirrhosis was considered an irreversible phenomenon. However, many experimental data have provided evidence of the reversibility of liver fibrosis. Moreover, multiple clinical studies have also shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples. As various etiologies are associated with liver fibrosis via integrated signaling pathways, a comprehensive understanding of the pathobiology of hepatic fibrogenesis is critical for improving clinical outcomes. Hepatic stellate cells play a central role in hepatic fibrogenesis upon their activation from a quiescent state. Collagen and other extracellular material components from activated hepatic stellate cells are deposited on, and damage, the liver parenchyma and vascular structures. Hence, inactivation of hepatic stellate cells can lead to enhancement of fibrolytic activity and could be a potential target of antifibrotic therapy. In this regard, continued efforts have been made to develop better treatments for underlying liver diseases and antifibrotic agents in multiple clinical and therapeutic trials; the best results may be expected with the integration of such evidence. In this article, we present the underlying mechanisms of fibrosis, current experimental and clinical evidence of the reversibility of liver fibrosis/cirrhosis, and new agents with therapeutic potential for liver fibrosis.
AB - In the past, liver cirrhosis was considered an irreversible phenomenon. However, many experimental data have provided evidence of the reversibility of liver fibrosis. Moreover, multiple clinical studies have also shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples. As various etiologies are associated with liver fibrosis via integrated signaling pathways, a comprehensive understanding of the pathobiology of hepatic fibrogenesis is critical for improving clinical outcomes. Hepatic stellate cells play a central role in hepatic fibrogenesis upon their activation from a quiescent state. Collagen and other extracellular material components from activated hepatic stellate cells are deposited on, and damage, the liver parenchyma and vascular structures. Hence, inactivation of hepatic stellate cells can lead to enhancement of fibrolytic activity and could be a potential target of antifibrotic therapy. In this regard, continued efforts have been made to develop better treatments for underlying liver diseases and antifibrotic agents in multiple clinical and therapeutic trials; the best results may be expected with the integration of such evidence. In this article, we present the underlying mechanisms of fibrosis, current experimental and clinical evidence of the reversibility of liver fibrosis/cirrhosis, and new agents with therapeutic potential for liver fibrosis.
KW - Fibrosis
KW - Hepatic stellate cells
KW - Liver cirrhosis
KW - Reversal
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85014810355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014810355&partnerID=8YFLogxK
U2 - 10.3904/kjim.2016.268
DO - 10.3904/kjim.2016.268
M3 - Review article
C2 - 28171717
AN - SCOPUS:85014810355
VL - 32
SP - 213
EP - 228
JO - Korean Journal of Internal Medicine
JF - Korean Journal of Internal Medicine
SN - 0494-4712
IS - 2
ER -